Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 5, 2014, Pages 1289-1296

  Lin, Hui ^a   Shen, Yong Chun ^a   Long, Hong Yu ^a   Wang, Hao ^a   Luo, Ze Yu ^a   Wei, Zi Xuan ^a   Hu, Shi Qi ^a   Wen, Fu Qiang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Malignant pleural mesothelioma; Meta analysis; Osteopontin

Indexed keywords

OSTEOPONTIN;

AREA UNDER THE CURVE; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HUMAN; LUNG DISEASE; MEASUREMENT ACCURACY; META ANALYSIS; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PUBLICATION; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SYSTEMATIC REVIEW (TOPIC);

EID: 84902489583     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Robinson BW and Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-1603.
2. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007; 62: ii1-ii19.
3. Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD and Wick MR. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-1331.
4. Tsujimura T, Torii I, Sato A, Song M, Fukuoka K, Hasegawa S and Nakano T. Pathological and molecular biological approaches to early mesothelioma. Int J Clin Oncol 2012; 17: 40-47.
5. Luo L, Shi HZ, Liang QL, Jiang J, Qin SM and Deng JM. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Resp Med 2010; 104: 149-156.
6. Fedarko NS, Jain A, Karadag A, Van Eman MR and Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 4060-4066.
7. Pantazopoulos I, Xanthos T, Boura P and Syrigos K. Mesothelin and osteopontin. Eur Respir J 2013; 42: 557-558.
8. Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A and Foddis R. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 2011; 6: 1587-1593.
9. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
10. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM; Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008; 149: 889-897.
11. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM and Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
12. Hu QJ, Shen YC, Jia LQ, Guo SJ, Long HY, Pang CS, Yang T and Wen FQ. Diagnostic performance of lung ultrasound in the diagnosis of pneumonia: a bivariate meta-analysis. Int J Clin Exp Med 2014; 7: 115-121.
13. Walter S. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002; 21: 1237-1256.
14. Lijmer JG, Bossuyt PM and Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 2002; 21: 1525-1537.
15. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C and Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564-1573.
16. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC and Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007; 13: 2928-35.
17. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ and Robinson BW. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008; 3:851-857.
18. Paleari L, Rotolo N, Imperatori A, Puzone R, Sessa F, Franzi F, Meacci E, Camplese P, Cesario A and Paganuzzi M. Osteopontin is not a specific marker in malignant pleural mesothelioma. Int J Biol Markers 2009; 24: 112-117.
19. Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A and Mutti L. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers 2010; 25: 164-170.
20. Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ and Robinson BW. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-which is best? Lung Cancer 2011; 74: 55-60.
21. Mundt F, Nilsonne G, Arslan S, Csürös K, Hillerdal G, Yildirim H, Metintas M, Dobra K and Hjerpe A. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS One 2013; 8: e72030.
22. Greillier L, Baas P, Welch JJ, Hasan B and Passioukov A. Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther 2008; 12: 375-90.
23. Jones CM and Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg 2005; 79: 16-20.
24. Glas AS, Lijmer JG, Prins MH, Bonsel GJ and Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56: 1129-1135.
25. Boutin C and Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer 1993; 72: 389-393.